Cart
sales@molnova.com
Poziotinib
CAS No. 1092364-38-9
Poziotinib( HM781-36B | NOV120101 )
Catalog No. M10347 CAS No. 1092364-38-9
Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 508 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePoziotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPoziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4.
-
DescriptionPoziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4; inhibits phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest; exerts synergistic effects with chemotherapeutic agents.Breast Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsHM781-36B | NOV120101
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorHER1|HER2|HER4
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1092364-38-9
-
Formula Weight491.3423
-
Molecular FormulaC23H21Cl2FN4O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
-
Chemical Name2-Propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
EGFR-IN-7
EGFR-IN-7 is a selective and potent EGFR kinase inhibitor.TQB3804 displayed potent enzymatic activities for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, and EGFRL858R/T790M with IC50 of 0.46, 0.13, 0.26, and 0.19 nM respectively, and has similar enzymatic activity for EGFRWT (IC50 = 1.07) to Osimertinib.
-
Intetumumab
Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.
-
PAT-505 B
PAT-505 is an orally available, selective and potent inhibitor of autologous epidermal growth factor (IC50 2 nM in Hep3B cells, 9.7 nM in human blood, 62 nM in mouse plasma).
